We demonstrated that YAP1 was significantly activated both in vitro and in vivo when ALK-rearranged lung cancer cells were treated with ALC, and the combinatorial inhibition of YAP1 and ALK achieved the suppression of initial survival in vitro and in vivo. This evidence concerns the gene YAP1 and lung carcinoma.